About the Authors
- Olga Hrydziuszko
-
Contributed equally to this work with: Olga Hrydziuszko, M. Thamara P. R. Perera
Affiliation School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom
- M. Thamara P. R. Perera
-
Contributed equally to this work with: Olga Hrydziuszko, M. Thamara P. R. Perera
Affiliation The Liver Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, United Kingdom
- Richard Laing
-
Affiliation The Liver Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, United Kingdom
- Jennifer Kirwan
-
Affiliation School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom
- Michael A. Silva
-
Affiliation The Liver Unit, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, United Kingdom
- Douglas A. Richards
-
Affiliation The Department of Pharmacology, School of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom
- Nick Murphy
-
Affiliation Department of Critical Care and Anaesthesia, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, B15 2TH, United Kingdom
- Darius F. Mirza
-
Affiliation School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom
- Mark R. Viant
-
* E-mail: m.viant@bham.ac.uk
Affiliation School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom
Competing Interests
This study was supported by a limited study grant by Astella’s Pharmaceuticals (UK) not exceeding 60000.00GBP to MTPRP, MAS and DFM for phase II study investigating biomarkers of poor allograft function following human liver transplantation. Astella’s Pharmaceuticals (UK) did not in any way have the access to the data not involved in any stage of the scientific data analysis or write up of this manuscript. The authors did not have any relationship with Astella’s Pharmaceuticals (UK) with regards to employment, consultancy, patents, products in development or marketed products. Author MTPRP has been given travel assistance to participate in two scientific conferences by Astella’s Pharmaceuticals (UK) not exceeding 5000.00GBP in the last three years declared under the Association of British Pharmaceutical Industry (ABPI) guidelines, and the data presented in this manuscript has not been presented in any of these meetings. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: MTPRP MAS NM DFM MRV. Data curation: OH MTPRP. Formal analysis: OH JK MRV. Funding acquisition: MTPRP MAS DFM. Investigation: OH JK MRV. Methodology: MTPRP OH JK DAR MRV. Project administration: MTPRP. Resources: MTPRP MAS DAR NM DFM MRV. Software: OH JK MRV. Supervision: DFM MRV. Validation: OH JK MRV. Writing – original draft: OH MTPRP. Writing – review & editing: MAS JK DAR NM DFM RL MRV.